the good Thanks, XXXX. want Prahlad, highlights to second I of with and the everyone. quarter start evening, for
Next, metrics. end some financial our on markets detail additional other I'll provide color served on and
update by finish second thinking providing how about the are I'll half XXXX. Lastly, of brief a we on
and quarter two entering remain expectations We've half full Starting the been organic with year. pleased off, on our our through focused first our performance. targets year targets. in Market first executing with conditions we roughly and the EPS line we're have achieved quarters, second growth and
medical to performed track analyzing initial is from in August. journal performance Year-on-year multisite in have to study of and Our model. on a continues results through six growth published Vanadis strong be well pregnancies our leading first year. remains the the accelerators set beat deal a months X,XXX
as genomics revenues Rob all testing cannabis and XXXX. Finally, have year-to-date outpaced mentioned, both of already
quarter second results. the to Turning
$XXX with and diagnostics by our business net X%. reproductive Reported a to immunodiagnostics X% sales revenue to a exchange By X% growth million acquisition strength revenue foreign and of tailwind. XX% lines. We headwind driven health business be pleased X% representing grew grew and included continue grew organically in organic our the business total as X%
Discovery a of I by provide sciences markets. some highlighted applied total businesses grew in organically & X% strength XX% on both weakness sales moment. Analytical representing and additional life by will in color in Solutions offset
remain with mid-single and a Pacific to during high grew single-digit similar in mixed, mid-single geographic the basis, what continues growth Asia Americas way organic organic Europe the The trends quarter. experienced digits. the revenue we to quarter lead first second On low grew digits growth,
solid pleased our basis were XX forward. and excellent margins points in we out operating we the continue expanded Operationally, expense in continued and improve see second to performance quarter, to with Adjusted operating cast quarter to by lovers. the profitability actions driven our second XX.X% going potential
operating expanded we by basis points XX Year-to-date, adjusted have year-over-year. margin
mentioned, per the adjusted XX% in was Rob XXXX an increase share our guidance. of with second and line earnings quarter was of of versus $X As
further Looking key our with start diagnostics our drivers business. within the into let's segments,
remarks, organic revenue my performance consistent across driven As and regions. broad-based all grew X% across in portfolio mentioned momentum our earlier by
enabled which We're with next-generation PerkinElmer genomics driven full our our toward our high-single-digits track to goals. genomic FDNA organically Reproductive business. which health collaboration past grew announced our year this services with by about continue pair testing technologies to genomics June, phenotyping business, excited
While time only we the estimated an of by disease dual in, in the early are rare the positive. extremely feedback the to been weeks diagnose newborns XX% diagnosis of clinical in has reduced already has pairing suspected incidence
mid-teens well to On the product the the immunodiagnostics organic all lines leading growth in for front quarter, performer segment.
recently testing. benchtop particularly excited are This as We fields in can disease, used such our launched system chemiluminescence SuperFlex gynecological cardiovascular, be infectious platform. about and
clinical It era and hospital a point-of-care a testing SuperFlex has convenience one director chemiluminescence advanced the its new testing. equipment in of China, by system. has precision described As efficiency point-of-care high the in and methodology reliability university major the with large ushered and of from of
installations new Vanadis, XX on XX our Applied We to track and become more solid And grew will think overall. as digits, as genomics comfortable the workflow upcoming serve of help we performance publication well adopters now year-end. customer remain shorten the with technology with and awareness our have mid-single additional validate unparalleled validation further a by as the and performance clinical with on publication. they assay the for time increased simplicity each
solutions, the we organic conditions the impacted second markets. by growth tough By in Turning was high analytical applied end experienced market, to quarter discovery single-digit and within pharma/biotech.
detection are of business of excited our Cisbio. the the future While particularly imaging potential about reagents continues following to we well, do and acquisition
the single-digit and generates that second high grew more an and now One reagents quarter platform double-digits basis. we're to quarter. expected in annual in revenues, well the to $XXX the leading annual business million Cisbio's integration in, on rate is than grow progressing We're mid
In softness in end globally. was particularly strong markets and mid-single in down primarily markets China industrial The demand. were our double-digits environmental China, Combined, by applied was up due driven Food legacy the were digits. industrial flat instrument markets and applied to cannabis portfolio. quarter analytical in soft,
controlled mostly on related Longer-term, that as product we in a in approvals of the issues and remain and bullish trade to are delays China, are as nature global export rhetoric. ongoing short-term these lot believe war well
back After lived myself with years I China our the times of June several teams For and in visit. in in officials. still ago Additional of well meeting half growth speed recently, government size by every the as many as our context, visiting the spent region I and China find amazed after having
and ahead my there talk with meetings decade-plus the was was which the my PerkinElmer's value in time there a of and it National Commerce was during local GXX and I rhetoric the clear meeting, ongoing history trade war about officials lot while leaders, Ministry commitments. our provincial that sides government all the both in China, on Health and of included China Commission, in five of they
tighten tomorrow. our could all Universally, to the collaborate open ideas exploring a to new to drive on more we and better opportunities bonds were officials had how
risk short-term, investment, to local additional about to country's health and team in prospects excited government ground. business and our we uncertainty creates candidly national our the with tension reputation and in and in trade U.S.-China have the I'm business the offices the region, on care the standing our commitment While the
below-the-line driven initiatives. by interest approximately was quarter shifting million adjusted rate timing of planning to expense XX%, for $XX items, the our quarterly adjusted and tax international was Now other and tax net
Free Turning the flow quarter was to the debt of and of million in quarter balance approximately and cash cash with was the adjusted million. billion cash. sheet, million free we $XX in the $XXX finished quarter $XX flow $X.X
and difference associated cash due adjusted between a to payments acquisitions. As reminder, prior reported with the the numbers
minute a working the seeing inventory. few and in of dynamics a to take capital receivables explain are me we Let areas
we seeing due later quarter shipments occurring in-quarter are greater customer demand First, a of percentage in the to patterns.
more in meet the As collections our a and inventory period less carry result, we needs. have customer to
Second, our in some we are models. evolving seeing a business stronger of growth
greater the in creates example, longer-term. our annuity subscription but cash a the in short-term, an business business informatics in As growth stronger less
to operations. Another cannabis, require liquidity short-term example relates customers where commence they as
year. business the we be and to in growth the inventory at higher EUROIMMUN outset now our to the due levels Third, MPI than anticipated expect of pipelines,
we flow increased XX% result of approximately As net longer-term of cash a now these changes, income and adjusted expect conversion to free growth.
quarter times, end of and at the to EBITDA X.X debt-to-adjusted now exited net with we times ratio year approximately we approximately a the leverage. Finally, X.X expect
performance growth including accelerators. half success earnings per of with Closing X% books XXXX, first the share, the on organic of growth, XX% we continued growth pleased are in our and our
As expect pace. Diagnostics back half we at a to high continue year, we of the transition similar to the single-digit
markets, in Solution As more range a are result of short-term growth the uncertainty our in single-digit organic to broadening & Analytical forecast. to year, compared mid segment X% prior applied we for full Discovery China to the X%
guidance X% original In turn, grow PerkinElmer to X% now of expect to X%. we versus our organically
of from $X.XX We year and revenue approximately billion, expect reported the including million headwinds to $XX $XX for foreign approximately million be from exchange Cisbio. contributions
exchange adjusted year our from $X.XX incremental foreign guide. are to an compared EPS of includes full headwind guidance which $X.XX prior prior $X.XX, to maintaining We range our
to basis We to adjusted points. our target expansion XXX of operating XXX committed also margin remain
$XX for rate share remain and under count expense, Finally, anticipate tax XXX year. slightly to and other the in interest our XX.X% million we a million
third quarter versus are prior of X% For million, XXXX, of reported the to exchange period. revenues $X organic headwind foreign approximately revenue comparable million we $XXX growth, of forecasting including the X% a representing
$X.XX. forecasting per we In share XQ, terms for are earnings adjusted guidance of
call prepared my for would concludes time, open This this questions. remarks. like Operator, we to at the
